NYSE: NNVC
NANOVIRICIDES, INC.CIK 0001379006 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (AMAT 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade NNVC commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed May 15, 2026 (period ending Mar 31, 2026). SEC XBRL (companyfacts) — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q3 ended Mar 31, 2026 | Q3 ended Mar 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 1.3 | 1.3 |
| General and administrative | 0.7 | 1.0 |
| Total operating expenses | 2.0 | 2.2 |
| Operating income | (2.0) | (2.2) |
| Other income/(expense), net | 0.04 | 0.03 |
| Basic earnings per share | (0.09) | (0.14) |
| Diluted earnings per share | (0.09) | (0.14) |
Consolidated Balance Sheets (Unaudited)
| Description | Mar 31, 2026 | Jun 30, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and equivalents | 3.2 | 1.6 |
| Prepaid expenses and other current assets | 0.2 | 0.1 |
| Total current assets | 3.4 | 1.7 |
| Property, plant and equipment, net | 6.5 | 6.8 |
| Identifiable intangible assets, net | 0.3 | 0.3 |
| TOTAL ASSETS | 10.2 | 8.8 |
| Current liabilities: | ||
| Accrued liabilities | 0.03 | 0.03 |
| Other current liabilities | 1.0 | 1.3 |
| Total current liabilities | 1.1 | 1.3 |
| Other long-term liabilities | 0.03 | |
| Total liabilities | 1.1 | 1.3 |
| Shareholders' equity: | ||
| Common stock | — | — |
| Capital in excess of stated value | 164.0 | 156.4 |
| Retained earnings (deficit) | (154.8) | (148.8) |
| Total shareholders' equity | 9.2 | 7.5 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 10.2 | 8.8 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Nine months ended Mar 31, 2026 | Nine months ended Mar 31, 2025 |
|---|---|---|
| Operating Activities: | ||
| Net cash from operating activities | (5.6) | (6.8) |
| Investing Activities: | ||
| Net cash from investing activities | (0.08) | (0.05) |
| Financing Activities: | ||
| Net cash from financing activities | 7.3 | 4.6 |
Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗